Arrowhead's ARO-C3 cut C3 levels by up to 89% and proteinuria by 41% in a Phase 1/2 trial. Additional results will be ...

The average of price targets set by Wall Street analysts indicates a potential upside of 58.6% in Kiniksa Pharmaceuticals (KNSA). While the effectiveness of this highly sought-after metric is ...

In addition to a continued focus on growing drug pipelines, and the increasing use of artificial intelligence (AI) and data ...

Nikhil Lalwani, President and CEO of ANI stated, "This transaction reflects our commitment to strengthening our Retina portfolio and maximizing the long-term value of ILUVIEN and YUTIQ. By eliminating ...

Pharmaceutical companies looked at this tax ... in Ireland or Singapore without changing real imports. And it would mean that the companies would have to pay tax in the U.S. at the headline ...

Learn more about whether Recursion Pharmaceuticals, Inc. or Veracyte, Inc. is a better investment based on AAII's A+ Investor ...

Kennedy can provide doctors and healthcare professionals with the information they need to truly determine if a drug is safe, ...

Encouraging preclinical data supporting the use of DNase-based technology to target NETosis and address difficult to treat cancers ...

August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new ...